`
`Select Country
`
`Apotex Launches First Generic Version of Merck's Nasonex®
`
`For Media Inquiries, Please Contact:
`Jordan Berman
`Global Director,
`Corporate Communications
`
` 4100 Weston Road,
`
`Apotex Inc.
`
`
`North York,
`ON, M9L 1P9
`Canada
` 416-401-7487
` Email (/global/contact-us/jordan-berman)
`
` ✉
`
`Press Center
`
`Mar 24, 2016
`Apotex Launches First Generic Version of Merck's Nasonex®
`Toronto, ON – Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex nasal spray (mometasone furoate monohydrate) in the
`®
`United States.
`
`Apotex's mometasone furoate nasal spray is a once-daily anti-allergen indicated for treatment of nasal congestion. According to IMS Health, Nasonex had
`®
`approximately $955.5 million in sales in the 12 months ending January 2016.
`
`"We are very pleased to make a more affordable version of this important allergy medicine available to the US public. Apotex is dedicated to bringing high quality
`versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the US health care system," said Apotex Chief
`Executive Officer and President, Dr. Jeremy B. Desai. "The amount of work required by all stakeholders to enable the launch of a first generic of this complexity cannot be
`overstated, and we appreciate the role of everyone involved, including the FDA who provided steady guidance throughout the development process," Desai added.
`
`FDA's approval of the company's generic version of Nasonex follows Apotex's successful Hatch-Waxman challenge of US Patent No. 6,127,353 (the '353 patent), which
`®
`Merck claimed covered the active ingredient. In June 2012, the US District Court for the District of New Jersey found that Apotex's product did not infringe the '353
`patent. The decision was upheld in June 2013 by the Federal Circuit.
`About Apotex
`Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately $2 billion.
`The company's US headquarters is based in Weston, Florida. With its worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. It produces
`300 medicines in 4,000 dosages and formats that are exported to 115 countries. It has 500 products under development and will spend $2 billion over the next 10 years
`on research and development.
`
`-30-
`
`Jordan Berman
`Global Director, Corporate Communications
`Apotex Inc.
`Direct: 416-401-7487
`Mobile: 647-272-2287
`Email (/global/contact-us/jordan-berman)
`
`Legal & Copyright Terms (/global/legal-copyright-terms) | Privacy Policy (/global/privacy-policy) | Global Business Ethics & Compliance (/global/global-business-ethics-
`compliance) | Public Advisories (/global/public-advisories)
`
`About Us
`(/global/about-
`us)
`About Apotex
`(/global/about-
`us/about-apotex)
`Corporate
`Responsibility
`(/global/about-
`us/corporate-
`responsibility)
`Our Leadership
`(/global/about-
`us/our-
`leadership)
`
`Products
`(/global/products)
`
`Healthcare
`Professionals
`(/global/healthcare-
`professionals)
`
`R & D (/global/r-
`n-d)
`Research &
`Development
`(/global/r-n-
`d/research-and-
`development)
`Bioequivalence
`(/global/r-n-
`d/bioequivalence)
`Clinical Studies
`(/global/r-n-
`d/clinical-studies)
`
`Business Opportunities
`(/global/business-
`opportunities)
`International Business
`Development Opportunities
`(/global/business-
`opportunities/international-
`business-development-
`opportunities)
`Co-Development
`(/global/business-
`opportunities/co-development)
`Out-Licensing in EMEA
`(/global/business-
`
`http://www1.apotex.com/global/about-us/press-center/2016/03/24/apotex-launches-first-generic-version-of-mercks-nasonex
`
`Careers
`(/global/careers)
`
`Contact Us
`(/global/contact-
`us)
`Apotex
`Worldwide
`(/global/contact-
`us/apotex-
`worldwide)
`
`Exhibit 1106
`IPR2017-00807
`ARGENTUM
`1/1
`
`000001
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
